Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioStar Pharmaceuticals 2008 net income up
BioStar Pharmaceuticals, a developer and manufacturer of pharmaceutical and medical nutrient products, has reported a net income of $6.69m, or $0.22 per diluted share, for 2008, compared to
BioStar Pharmaceuticals, a developer and manufacturer of pharmaceutical and medical nutrient products, has reported a net income of $6.69m, or $0.22 per diluted share, for 2008, compared to
Genentech, a biotechnology company, has initiated a phased voluntary withdrawal of the psoriasis drug Raptiva from the US market. The company’s decision is based on the association of
Amarin, a biopharmaceutical company, has announced that the European Medicines Agency has accepted for review the company’s marketing authorization application for AMR101 in patients with Huntington’s disease. The
Most recently, Dr Rioux was chief medical officer (CMO) of FerroKin Biosciences, a developer of iron chelator for treatment of anemias. Prior to that, Dr Rioux was CMO
Othera Pharmaceuticals, a specialty pharmaceutical company, has reported positive interim data from its Phase II trial of OT-551 in treating geographic atrophy, an advanced form of dry age-related
This patent infringement suit was originally filed in 2004 and relates to the use of lasers for endovenous ablation. CoolTouch will license the Navarro patent and pay royalties
Schering-Plough’s majority owned affiliate in India, Fulford India, has received approval for its Viraferonpeg, the pegylated interferon therapy in combination with Rebetol, for retreating adult patients with chronic
Keppra XR was approved by the FDA based on data from an international clinical study of 158 epilepsy patients with partial-onset seizures who added 1,000mg of Keppra XR
The transaction includes a 10-year contract for Express Scripts to provide services to WellPoint following closing of the transaction. The transition to Express Scripts’s platform and products will
Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The